These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18449003)

  • 21. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    J Thorac Oncol; 2006 Jul; 1(6):545-50. PubMed ID: 17409915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
    Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
    Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
    Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
    Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Farley C; Shipley DL; Bearden JD; Gandhi J; Ann Houston G; Anthony Greco F
    Cancer; 2007 Nov; 110(9):2027-34. PubMed ID: 17823908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
    Dong X; Zhao X; Hao Y; Wei Y; Yin Q; Du J
    Clin Lung Cancer; 2013 Nov; 14(6):680-7. PubMed ID: 23910066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
    Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
    Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
    Katakami N; Sugiura T; Nogami T; Yamamoto H; Negoro S; Nakano T; Okamoto N; Takada Y; Kodama K; Ariyoshi Y
    Lung Cancer; 2004 Jan; 43(1):93-100. PubMed ID: 14698543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
    J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
    J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of elderly patients with advanced non-small cell lung cancer in Turkey.
    Yildirim Y; Ozyilkan O; Calikusu Z; Akcali Z; Akcay Y; Demirhan B
    Asian Pac J Cancer Prev; 2009; 10(4):699-700. PubMed ID: 19827898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
    Ardizzoia A; Acquati M; Fagnani D; Giordano M; Visini M; Scanni A; Quattrone A; Fusco O; Vergani C; Casartelli C; Tagliabue P; Malugani F;
    Lung; 2004; 182(1):1-8. PubMed ID: 14752667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
    Pallis AG; Agelaki S; Kakolyris S; Kotsakis A; Kalykaki A; Vardakis N; Papakotoulas P; Agelidou A; Geroyianni A; Agelidou M; Hatzidaki D; Mavroudis D; Georgoulias V;
    Lung Cancer; 2008 Dec; 62(3):356-63. PubMed ID: 18501466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.